PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies
出版年份 2017 全文链接
标题
PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies
作者
关键词
-
出版物
Cancers
Volume 9, Issue 12, Pages 172
出版商
MDPI AG
发表日期
2017-12-19
DOI
10.3390/cancers9120172
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition
- (2017) Ahmad Najem et al. EUROPEAN JOURNAL OF CANCER
- Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation
- (2017) David S. Liu et al. Nature Communications
- Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine
- (2016) Andrea Orue et al. BMC CANCER
- Anti-leukaemic effects induced by APR-246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells
- (2016) Dina Ali et al. BRITISH JOURNAL OF HAEMATOLOGY
- APR-246 (PRIMA-1 MET ) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines
- (2016) Christophe Deben et al. CANCER LETTERS
- p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib
- (2016) Mohammad Krayem et al. EUROPEAN JOURNAL OF CANCER
- TP53Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data
- (2016) Liacine Bouaoun et al. HUMAN MUTATION
- Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
- (2016) N.C. Synnott et al. INTERNATIONAL JOURNAL OF CANCER
- PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells
- (2016) NOBUHISA YOSHIKAWA et al. ONCOLOGY REPORTS
- Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer
- (2016) Åsa Fransson et al. Journal of Ovarian Research
- miRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc
- (2016) Manujendra N. Saha et al. Oncotarget
- Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status
- (2016) Mariia Patyka et al. Oncotarget
- PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation
- (2016) Phaik Ju Teoh et al. Oncotarget
- PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK
- (2016) Tao Lu et al. Oncotarget
- Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy
- (2016) Vladimir J. N. Bykov et al. Frontiers in Oncology
- PRIMA-1MET induces death in soft-tissue sarcomas cell independent of p53
- (2015) Thomas Grellety et al. BMC CANCER
- PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53
- (2015) Mona Sobhani et al. CANCER BIOLOGY & THERAPY
- Stimulation of Suicidal Erythrocyte Death by PRIMA-1
- (2015) Caterina Faggio et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Silencing of CD24 Enhances the PRIMA-1-Induced Restoration of Mutant p53 in Prostate Cancer Cells
- (2015) W. Zhang et al. CLINICAL CANCER RESEARCH
- APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma
- (2015) David S H Liu et al. GUT
- Zn(II)-curc targets p53 in thyroid cancer cells
- (2015) ALESSIA GARUFI et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- 3-BrPA eliminates human bladder cancer cells with highly oncogenic signatures via engagement of specific death programs and perturbation of multiple signaling and metabolic determinants
- (2015) Eumorphia G. Konstantakou et al. Molecular Cancer
- CRISPR-Cas9–based target validation for p53-reactivating model compounds
- (2015) Michael Wanzel et al. Nature Chemical Biology
- APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
- (2015) N Mohell et al. Cell Death & Disease
- PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms
- (2015) Xiao-Lan Li et al. Oncotarget
- Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage
- (2015) Kamila A. Marzec et al. Oncotarget
- TP53 transcription factor for the NEDD9/HEF1/Cas-L gene: potential targets in Non-Small Cell Lung Cancer treatment
- (2015) Bénédicte ROUSSEAU et al. Scientific Reports
- Array-based genome-wide RNAi screening to identify shRNAs that enhance p53-related apoptosis in human cancer cells
- (2015) Masashi Idogawa et al. Oncotarget
- PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance
- (2014) B. Tessoulin et al. BLOOD
- Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
- (2014) Patricia A.J. Muller et al. CANCER CELL
- Wild type p53 reactivation: From lab bench to clinic
- (2014) Galina Selivanova FEBS LETTERS
- PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines
- (2014) Patricia Izetti et al. INVESTIGATIONAL NEW DRUGS
- PRIMA-1 Selectively Induces Global DNA Demethylation in p53 Mutant-Type Thyroid Cancer Cells
- (2014) Wei Qiang et al. Journal of Biomedical Nanotechnology
- PRIMA-1, a Mutant p53 Reactivator, Restores the Sensitivity ofTP53Mutant-Type Thyroid Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A
- (2014) Bo Cui et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- PRIMA-1 induces autophagy in cancer cells carrying mutant or wild type p53
- (2013) Debora Russo et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Variability in functional p53 reactivation by PRIMA-1Met/APR-246 in Ewing sarcoma
- (2013) D N T Aryee et al. BRITISH JOURNAL OF CANCER
- Prima-1 induces apoptosis in bladder cancer cell lines by activating p53
- (2013) CB Piantino et al. Clinics
- PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa
- (2013) Manujendra N. Saha et al. MOLECULAR CANCER THERAPEUTICS
- Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1MET
- (2013) R. Shalom-Feuerstein et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- APR-246/PRIMA-1MET rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations
- (2013) J. Shen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
- (2013) X Peng et al. Cell Death & Disease
- Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53
- (2013) Christopher D. Wassman et al. Nature Communications
- PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation
- (2013) Noriko Kobayashi et al. Journal of Ovarian Research
- Hypoxia, Mn-SOD and H2O2 regulate p53 reactivation and PRIMA-1 toxicity irrespective of p53 status in human breast cancer cells
- (2012) Manuel Rieber et al. BIOCHEMICAL PHARMACOLOGY
- Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
- (2012) Sören Lehmann et al. JOURNAL OF CLINICAL ONCOLOGY
- PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo
- (2011) Wenjie Bao et al. CELL CYCLE
- PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53
- (2011) R. Zandi et al. CLINICAL CANCER RESEARCH
- Reactivation of p53 mutants by p53 reactivation and induction of massive apoptosis in thyroid cancer cells
- (2011) Rosa Linda Messina et al. INTERNATIONAL JOURNAL OF CANCER
- PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells
- (2010) Debora Russo et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors
- (2010) Yayun Liang et al. BREAST CANCER RESEARCH AND TREATMENT
- APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells
- (2010) Dina Ali et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- PRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73
- (2010) N Rökaeus et al. ONCOGENE
- p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma
- (2010) Jong-Lyel Roh et al. ORAL ONCOLOGY
- Therapeutic targeting of p53 by small molecules
- (2010) Galina Selivanova SEMINARS IN CANCER BIOLOGY
- PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
- (2009) Jeremy M.R. Lambert et al. CANCER CELL
- MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in human lung cancer cells
- (2009) Wenrui Duan et al. INTERNATIONAL JOURNAL OF CANCER
- PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein
- (2009) György Stuber et al. Molecular Cancer
- Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis
- (2009) J M R Lambert et al. ONCOGENE
- PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells
- (2008) R. Magrini et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
- (2008) F. M. Boeckler et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PRIMA-1met radiosensitizes prostate cancer cells independent of their MTp53-status
- (2008) Stéphane Supiot et al. RADIOTHERAPY AND ONCOLOGY
- In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249
- (2007) H. Shi et al. CARCINOGENESIS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now